Chang C - Search Results

1

Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study.

Qiu L, Xia Z, Fu C, Chen W, Chang C, Fang B, An G, Wei Y, Cai Z, Gao S, Weng J, Chen L, Jing H, Li F, Liu Z, Chen X, Liu J, Wang A, Yu Y, Xiang W, Lynch K, Yu Z, Fu W. Qiu L, et al. Among authors: chang c. BMC Med. 2022 Apr 5;20(1):108. doi: 10.1186/s12916-022-02305-4. BMC Med. 2022. PMID: 35379237 Free PMC article. Clinical Trial.

2

[The affection of bisphosphonates combined with chemotherapy on bone metabolism index in multiple myeloma].

Zhang X, Chang CK, Wu LY, Zhang Z, Zhou LY, Xiao C, Li X. Zhang X, et al. Among authors: chang ck. Zhonghua Xue Ye Xue Za Zhi. 2011 Oct;32(10):660-3. Zhonghua Xue Ye Xue Za Zhi. 2011. PMID: 22339822 Clinical Trial. Chinese.

3

[Influence of bisphosphonate combined with chemotherapy on bone mineral density of patients with multiple myeloma].

Zhang X, Chang CK, Zhang Z, Zhao YS, Xiao C, Li X. Zhang X, et al. Among authors: chang ck. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012 Oct;20(5):1135-8. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012. PMID: 23114134 Clinical Trial. Chinese.

4

The efficacy and toxicity of the CHG priming regimen (low-dose cytarabine, homoharringtonine, and G-CSF) in higher risk MDS patients relapsed or refractory to decitabine.

Xiu C, Li X, Wu L, Xu F, He Q, Zhang Z, Wu D, Song L, Su J, Zhou L, Zhao Y, Tao Y, Chang C. Xiu C, et al. Among authors: chang c. J Cancer Res Clin Oncol. 2019 Dec;145(12):3089-3097. doi: 10.1007/s00432-019-03031-w. Epub 2019 Sep 26. J Cancer Res Clin Oncol. 2019. PMID: 31559495 Clinical Trial.

5

Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single-arm, open-label, phase 2, multicenter study.

Zhang Y, Zhou H, Duan M, Gao S, He G, Jing H, Li J, Ma L, Zhu H, Chang C, Du X, Hong M, Li X, Liu Q, Wang W, Xu N, Yang H, Lu B, Yin H, Wu L, Suo S, Zhao Q, Xiao Z, Jin J. Zhang Y, et al. Among authors: chang c. Am J Hematol. 2023 Oct;98(10):1588-1597. doi: 10.1002/ajh.27033. Epub 2023 Jul 20. Am J Hematol. 2023. PMID: 37470365 Clinical Trial.

6

[Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA].

Su JY, Chang CK, Zhang X, Zhou LY, Song LQ, Xu L, Wu LY, He Q, Li X. Su JY, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Apr;17(2):459-63. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009. PMID: 19379588 Clinical Trial. Chinese.

7

Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.

Wu L, Li X, Su J, Chang C, He Q, Zhang X, Xu L, Song L, Pu Q. Wu L, et al. Among authors: chang c. Leuk Lymphoma. 2009 Sep;50(9):1461-7. doi: 10.1080/10428190903096719. Leuk Lymphoma. 2009. PMID: 19672772 Clinical Trial.

8

[Yield of CD34(+) cells in graft can be increased significantly by G-CSF used at appropriate time after chemotherapy for AutoPBSCT].

Xu L, Chang CK, Gan WJ, Su JY, Zhang X, Wu LY, Song LX, He Q, Zhou LY, Xiao C, Liu H, Li X. Xu L, et al. Among authors: chang ck. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Jun;19(3):759-63. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011. PMID: 21729566 Clinical Trial. Chinese.

9

Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS.

Wu L, Li X, Su J, He Q, Zhang X, Chang C, Pu Q. Wu L, et al. Among authors: chang c. J Cancer Res Clin Oncol. 2011 Oct;137(10):1563-9. doi: 10.1007/s00432-011-1020-2. Epub 2011 Aug 4. J Cancer Res Clin Oncol. 2011. PMID: 21845438

10

Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.

Song LX, Xu L, Li X, Chang CK, Zhang Y, Wu LY, He Q, Zhang QX, Li X. Song LX, et al. Ann Hematol. 2012 Dec;91(12):1879-86. doi: 10.1007/s00277-012-1550-y. Epub 2012 Aug 16. Ann Hematol. 2012. PMID: 22895556 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

29,323 results

Search Page